Table 1 Baseline (before receipt of antiretroviral prophylaxis) characteristics of the pregnant women (transmitting or nontransmitting mothers included.

Slides:

Advertisements

Similar presentations

HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.

Advertisements

Dr. S.K CHATURVEDI Dr. KANUPRIYA CHATURVEDI

Towards Universal Access Recommendations for a Public Health Approach BASED ON WHO GUIDELINES Antiretroviral Drugs for Treating Pregnant Women and Preventing.

STDs Valerie Robinson D.O.. Prevention Abstinence Risk reduction Vaccines Male or female condoms Cervical diaphragm might protect against cervical GC,

Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA,

The Global Response to AIDS: Does It Pass the Test for Women? Peter Piot Institute for Global Health Imperial College.

HIV Treatment and Care Research priorities Facilitator – Dr Saphonn Vonthanak 12 participants 29 agreed topics –not grouped on methodology or subject category.

1 Resistances: The evidences The point of view of an epidemiologist PMTCT Programmes: What needs to change? MSF Expert Round Table - Geneva - June 23-24,

HIV DISEASE IN PREGNANCY

Epidémiologie Problème mondial / problématique en fonction de l’âge et le sexe Mise en place de la prophylaxie.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

HIV/AIDS By: Shawn Dye

Sexually Transmitted Diseases Caused by. Trichomonas.

Estimating the Impact and Needs for Children and PMTCT Making sense: Understanding the numbers: from HIV surveillance to national and global HIV burden.

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

7th December 2011 Symposium ANRS HIV testing among male partners Coverage, associated factors and prenatal intervention in Cameroon ANRS Prenahtest.

Universal Access Charter The Universal Access Charter is intended to be the voice of communities and civil societies around the world; The Charter is a.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 1. Baseline Characteristics of the 36,636 Study Subjects

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 1 Characteristics of the 968 Women in the Study Group

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

From: Rotarix: A Rotavirus Vaccine for the World

Background Results Methods Conclusion

Table 4. Effect of vaccination status on serogroup C serum bactericidal antibody (SBA) titers, IgG levels, and avidity indices (AIs) in acute and convalescent.

Table 1 Criteria for proven invasive fungal disease except for endemic mycoses. From: Revised Definitions of Invasive Fungal Disease from the European.

From: Postinfectious Irritable Bowel Syndrome

Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type,

Table 5 Sample format for results of Streptococcus pneumoniae isolate testing in a laboratory that routinely performs only oxacillin disk tests for penicillin.

Figure 1 Annual per-capita consumption of all fermented milks and yogurt only in selected countries in Europe and North America [3, 4]. From: Probiotic.

Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation.

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Antiretroviral therapy coverage in sub-Saharan Africa,

Immune-based interventions to prevent postnatal HIV-1 transmission

M. Colafigli, C. Torti, E. M. Trecarichi, L. Albini, A. Rosi, V

Group B streptococcal colonization and transmission dynamics in pregnant women and their newborns in Nigeria: implications for prevention strategies

A. Marangoni, A. Moroni, E. Tridapalli, M. G. Capretti, G. Farneti, G

A. Marangoni, A. Moroni, E. Tridapalli, M. G. Capretti, G. Farneti, G

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Cornelia van Zyl, Maretha J. Visser Reproductive BioMedicine Online

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Single-dose antibiotic prophylaxis for urinary catheter removal does not reduce the risk of urinary tract infection in surgical patients: a randomized.

Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage.

Transmitted drug-resistance in human immunodeficiency virus-infected adult population in El Salvador, Central America Á. Holguín, G. Yebra, L. Martín,

J. Logar, B. Šoba, T. Premru-Sršen, Ž. Novak-Antolič

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure.

earching the best evidence

Combating the spread of carbapenemases in Enterobacteriaceae: a battle that infection prevention should not lose P. Savard, T.M. Perl Clinical Microbiology.

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009 S. Di Giambenedetto, M. Prosperi, I.

F. De Massis, A. Di Girolamo, A. Petrini, E. Pizzigallo, A. Giovannini

Conflicting of interest disclosure: None

C. Tamalet, P. Colson, E. Decroly, C. Dhiver, I. Ravaux, A. Stein, D

Intrapartum Group B streptococcus detection by rapid polymerase chain reaction assay for the prevention of neonatal sepsis B. Martinez de Tejada, R.E.

E. Tacconelli Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

HIV infections newly diagnosed in injecting drug users and men who have sex with men, by country, and year of report, 2002– Injecting drug users.

Presentation transcript:

Table 1 Baseline (before receipt of antiretroviral prophylaxis) characteristics of the pregnant women (transmitting or nontransmitting mothers included or not included in the resistance study)—Agence Nationale de Recherches sur le SIDA 1201.1 Ditrame Plus, Abidjan, Côte d'ivoire. From: Low Risk of Nevirapine Resistance Mutations in the Prevention of Mother-to-Child Transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Côte d'Ivoire J Infect Dis. 2006;193(4):482-487. doi:10.1086/499966 J Infect Dis | © 2006 by the Infectious Diseases Society of America 1